Suppr超能文献

人血浆中密度脂蛋白(IDL)的细胞代谢

Cellular metabolism of human plasma intermediate-density lipoprotein (IDL).

作者信息

Friedman G, Gavish D, Vogel T, Eisenberg S

机构信息

Department of Medicine B, Hadassah University Hospital, Jerusalem, Israel.

出版信息

Biochim Biophys Acta. 1990 May 1;1044(1):118-26. doi: 10.1016/0005-2760(90)90226-n.

Abstract

The cellular metabolism of human plasma intermediate-density lipoprotein (IDL) was investigated in cultured human skin fibroblasts and hepG-2 cell in the absence and presence of exogenous recombinant or plasmatic apo E-3. IDL (d 1.006-1.019 g/ml) and LDL (d 1.019-1.063 g/ml) were prepared by centrifugation from the plasma of apo E-3/3 or 4/3 normolipidemic human subjects. Without added apo E-3, IDL binding and cell association are similar or slightly reduced while their degradation is one third to one half. This results in degradation to binding ratios for IDL that are half those for LDL. Exogenous apo E-3 enhances binding, association and degradation of IDL by 50-150%, but the degradation to binding ratio remains low. Exogenous apo E-3 also increased the ability of IDL but not LDL, to down-regulate the incorporation of [14C]acetate to sterol by the cells. The optimal concentration of apo E-3 is 4 micrograms protein/10 micrograms IDL protein and at that concentration appreciable amounts of the apo E are found associated with the lipoprotein. Apo E-2 has no effect on the cellular metabolism of IDL and apo E-3 is not effective in receptor-negative human fibroblasts. Monoclonal antibodies that block apo E binding to B,E (LDL) receptor (1D7) abolish the cellular metabolism of IDL while antibodies against B-100 (4G3) are ineffective. In competitive binding experiments, IDL is slightly more effective than LDL in displacing 125I-LDL from receptors in hepG-2 cells and appreciably more effective than LDL when tested against 125I-IDL. Apo E-3 increases the capacity of IDL to compete with either 125I-LDL or 125I-IDL. Addition of apo E-3 also increases the binding affinity of IDL to hepG-2 receptors, with Kd values of 2.50, 0.93 micrograms protein/ml, respectively. The study demonstrates the essential role that functional apo E molecules play in the interaction of human IDL with cellular receptors. Yet, in spite of presence of apo E in IDL (2-3 molecules/particle) and enrichment of IDL with apo E-3 (to 4-5 molecules/particle) the proteolytic degradation of the lipoprotein by specific cellular receptor is similar to LDL.

摘要

在有或没有外源性重组或血浆载脂蛋白E-3(apo E-3)存在的情况下,研究了人血浆中密度脂蛋白(IDL)在培养的人皮肤成纤维细胞和HepG-2细胞中的细胞代谢。通过离心从apo E-3/3或4/3血脂正常的人类受试者血浆中制备IDL(密度1.006 - 1.019 g/ml)和低密度脂蛋白(LDL,密度1.019 - 1.063 g/ml)。在不添加apo E-3的情况下,IDL的结合和细胞关联相似或略有降低,但其降解程度为三分之一至二分之一。这导致IDL的降解与结合比率仅为LDL的一半。外源性apo E-3可使IDL的结合、关联和降解增强50% - 150%,但降解与结合比率仍然较低。外源性apo E-3还增加了IDL(而非LDL)下调细胞将[14C]乙酸掺入固醇的能力。apo E-3的最佳浓度为4微克蛋白质/10微克IDL蛋白质,在此浓度下可发现相当数量的apo E与脂蛋白相关联。apo E-2对IDL的细胞代谢无影响,且apo E-3对受体阴性的人成纤维细胞无效。阻断apo E与B、E(LDL)受体结合的单克隆抗体(1D7)可消除IDL的细胞代谢,而针对B-100的抗体(4G3)则无效。在竞争性结合实验中,IDL在从HepG-2细胞受体上置换125I-LDL方面比LDL略有效,而在针对125I-IDL进行测试时比LDL明显更有效。apo E-3增加了IDL与125I-LDL或125I-IDL竞争的能力。添加apo E-3还增加了IDL与HepG-2受体的结合亲和力,其解离常数(Kd)值分别为2.50、0.93微克蛋白质/毫升。该研究证明了功能性apo E分子在人IDL与细胞受体相互作用中所起的重要作用。然而,尽管IDL中存在apo E(2 - 3个分子/颗粒)且用apo E-3使IDL富集(至4 - 5个分子/颗粒),但脂蛋白通过特定细胞受体的蛋白水解降解与LDL相似。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验